CA2991529C - Pre-frontal cortex processing disorder, gait and limb impairment treatment - Google Patents
Pre-frontal cortex processing disorder, gait and limb impairment treatment Download PDFInfo
- Publication number
- CA2991529C CA2991529C CA2991529A CA2991529A CA2991529C CA 2991529 C CA2991529 C CA 2991529C CA 2991529 A CA2991529 A CA 2991529A CA 2991529 A CA2991529 A CA 2991529A CA 2991529 C CA2991529 C CA 2991529C
- Authority
- CA
- Canada
- Prior art keywords
- methylphenidate
- gait
- disorder
- dextro
- impairment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000006735 deficit Effects 0.000 title claims abstract description 149
- 230000005021 gait Effects 0.000 title claims abstract description 125
- 210000002442 prefrontal cortex Anatomy 0.000 title claims abstract description 23
- 238000012545 processing Methods 0.000 title claims abstract description 23
- 238000011282 treatment Methods 0.000 title claims description 39
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 claims abstract description 144
- 229960001344 methylphenidate Drugs 0.000 claims abstract description 140
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 111
- 208000035475 disorder Diseases 0.000 claims abstract description 88
- 206010008129 cerebral palsy Diseases 0.000 claims abstract description 55
- 208000006289 Rett Syndrome Diseases 0.000 claims abstract description 46
- 208000009575 Angelman syndrome Diseases 0.000 claims abstract description 38
- 201000010099 disease Diseases 0.000 claims abstract description 22
- 201000006417 multiple sclerosis Diseases 0.000 claims abstract description 21
- 208000001914 Fragile X syndrome Diseases 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims description 54
- 230000006872 improvement Effects 0.000 claims description 21
- 230000000694 effects Effects 0.000 claims description 19
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims description 18
- 230000003292 diminished effect Effects 0.000 claims description 17
- -1 alkyl phenidate Chemical compound 0.000 claims description 16
- 229960003433 thalidomide Drugs 0.000 claims description 16
- 230000000573 anti-seizure effect Effects 0.000 claims description 11
- 206010067130 Spastic diplegia Diseases 0.000 claims description 9
- 239000000221 dopamine uptake inhibitor Substances 0.000 claims description 8
- AZVPADMEIMLODT-UHFFFAOYSA-N propan-2-yl 2-phenyl-2-piperidin-2-ylacetate Chemical group C=1C=CC=CC=1C(C(=O)OC(C)C)C1CCCCN1 AZVPADMEIMLODT-UHFFFAOYSA-N 0.000 claims description 8
- 210000004291 uterus Anatomy 0.000 claims description 8
- 206010051290 Central nervous system lesion Diseases 0.000 claims description 6
- GRFNBEZIAWKNCO-UHFFFAOYSA-N 3-pyridinol Chemical compound OC1=CC=CN=C1 GRFNBEZIAWKNCO-UHFFFAOYSA-N 0.000 claims description 3
- ZDZDSZQYRBZPNN-UHFFFAOYSA-N 4,5,6,7-tetrahydro-[1,2]oxazolo[5,4-c]pyridin-6-ium-3-olate;hydrochloride Chemical compound Cl.C1NCCC2=C1ONC2=O ZDZDSZQYRBZPNN-UHFFFAOYSA-N 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 230000007659 motor function Effects 0.000 claims description 3
- 230000001272 neurogenic effect Effects 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 229940094659 Dopamine reuptake inhibitor Drugs 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000003414 extremity Anatomy 0.000 description 60
- 239000003368 psychostimulant agent Substances 0.000 description 27
- 210000002683 foot Anatomy 0.000 description 16
- 230000000144 pharmacologic effect Effects 0.000 description 16
- 229940053650 focalin Drugs 0.000 description 14
- 210000002414 leg Anatomy 0.000 description 14
- 230000005856 abnormality Effects 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 208000002193 Pain Diseases 0.000 description 10
- 230000001430 anti-depressive effect Effects 0.000 description 10
- 239000000935 antidepressant agent Substances 0.000 description 10
- 206010003062 Apraxia Diseases 0.000 description 8
- ZXRVKCBLGJOCEE-UHFFFAOYSA-N Gaboxadol Chemical compound C1NCCC2=C1ONC2=O ZXRVKCBLGJOCEE-UHFFFAOYSA-N 0.000 description 8
- 210000003423 ankle Anatomy 0.000 description 8
- 230000001148 spastic effect Effects 0.000 description 8
- 125000000217 alkyl group Chemical group 0.000 description 7
- 230000002411 adverse Effects 0.000 description 6
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
- 230000037230 mobility Effects 0.000 description 6
- 208000018737 Parkinson disease Diseases 0.000 description 5
- 229940005513 antidepressants Drugs 0.000 description 5
- 206010019468 Hemiplegia Diseases 0.000 description 4
- 208000011644 Neurologic Gait disease Diseases 0.000 description 4
- 230000002146 bilateral effect Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 description 4
- 208000003508 Botulism Diseases 0.000 description 3
- 208000007101 Muscle Cramp Diseases 0.000 description 3
- 208000008238 Muscle Spasticity Diseases 0.000 description 3
- 208000005392 Spasm Diseases 0.000 description 3
- 208000037919 acquired disease Diseases 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000003028 elevating effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000036651 mood Effects 0.000 description 3
- 229960001816 oxcarbazepine Drugs 0.000 description 3
- 208000037821 progressive disease Diseases 0.000 description 3
- 208000018198 spasticity Diseases 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- 108010012934 Albumin-Bound Paclitaxel Proteins 0.000 description 2
- 206010003591 Ataxia Diseases 0.000 description 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 2
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 2
- 206010009346 Clonus Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 206010013033 Diplegia Diseases 0.000 description 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
- 206010017577 Gait disturbance Diseases 0.000 description 2
- 101150083522 MECP2 gene Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 206010034701 Peroneal nerve palsy Diseases 0.000 description 2
- 206010037714 Quadriplegia Diseases 0.000 description 2
- 206010040030 Sensory loss Diseases 0.000 description 2
- 206010068872 Toe walking Diseases 0.000 description 2
- 229940028652 abraxane Drugs 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 229960000794 baclofen Drugs 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 230000006931 brain damage Effects 0.000 description 2
- 231100000874 brain damage Toxicity 0.000 description 2
- 208000029028 brain injury Diseases 0.000 description 2
- 210000000133 brain stem Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000003412 degenerative effect Effects 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 229940052760 dopamine agonists Drugs 0.000 description 2
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000013265 extended release Methods 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000000118 neural pathway Anatomy 0.000 description 2
- 230000010004 neural pathway Effects 0.000 description 2
- 108010027737 peginterferon beta-1a Proteins 0.000 description 2
- 229940007060 plegridy Drugs 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- YFGHCGITMMYXAQ-UHFFFAOYSA-N 2-[(diphenylmethyl)sulfinyl]acetamide Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 208000019722 Delayed speech and language development Diseases 0.000 description 1
- 206010012559 Developmental delay Diseases 0.000 description 1
- 102000006441 Dopamine Plasma Membrane Transport Proteins Human genes 0.000 description 1
- 108010044266 Dopamine Plasma Membrane Transport Proteins Proteins 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 208000005622 Gait Ataxia Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010072388 Methyl-CpG-Binding Protein 2 Proteins 0.000 description 1
- 102100039124 Methyl-CpG-binding protein 2 Human genes 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 206010033892 Paraplegia Diseases 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 108010057266 Type A Botulinum Toxins Proteins 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 229940089093 botox Drugs 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 208000007118 chronic progressive multiple sclerosis Diseases 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 210000001653 corpus striatum Anatomy 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000001037 epileptic effect Effects 0.000 description 1
- 210000003811 finger Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001652 frontal lobe Anatomy 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- 229950004346 gaboxadol Drugs 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004247 hand Anatomy 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 229940073062 imuran Drugs 0.000 description 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 208000011977 language disease Diseases 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- DUGOZIWVEXMGBE-STQMWFEESA-N methyl (S)-phenyl[(S)-piperidin-2-yl]acetate Chemical compound C([C@H]1[C@@H](C(=O)OC)C=2C=CC=CC=2)CCCN1 DUGOZIWVEXMGBE-STQMWFEESA-N 0.000 description 1
- JUMYIBMBTDDLNG-UHFFFAOYSA-N methylphenidate hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(C(=O)OC)C1CCCC[NH2+]1 JUMYIBMBTDDLNG-UHFFFAOYSA-N 0.000 description 1
- 229960001165 modafinil Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000009427 motor defect Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000007472 neurodevelopment Effects 0.000 description 1
- 230000003557 neuropsychological effect Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 201000005936 periventricular leukomalacia Diseases 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002360 prefrontal effect Effects 0.000 description 1
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- INGSNVSERUZOAK-UHFFFAOYSA-N ritalinic acid Chemical class C=1C=CC=CC=1C(C(=O)O)C1CCCCN1 INGSNVSERUZOAK-UHFFFAOYSA-N 0.000 description 1
- 206010039722 scoliosis Diseases 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 208000037921 secondary disease Diseases 0.000 description 1
- 230000000276 sedentary effect Effects 0.000 description 1
- 208000037118 sensory ataxia Diseases 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 201000007770 spastic cerebral palsy Diseases 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000003813 thumb Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000011491 transcranial magnetic stimulation Methods 0.000 description 1
- 229940061414 trileptal Drugs 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/793,829 US9307942B2 (en) | 2011-05-19 | 2015-07-08 | Treatment for cerebral palsy gait impairment |
| US14/793,829 | 2015-07-08 | ||
| US14/881,516 | 2015-10-13 | ||
| US14/881,516 US9333198B2 (en) | 2011-05-19 | 2015-10-13 | Treatment for cerebral palsy gait impairment |
| US14/971,325 US9408838B2 (en) | 2011-05-19 | 2015-12-16 | Treatment for cerebral palsy gait impairment |
| US14/971,325 | 2015-12-16 | ||
| US15/075,375 US9682073B2 (en) | 2011-05-19 | 2016-03-21 | Pre-frontal cortex processing disorder gait and limb impairments treatment |
| US15/075,375 | 2016-03-21 | ||
| PCT/US2016/037367 WO2017007577A1 (en) | 2015-07-08 | 2016-06-14 | Pre-frontal cortex processing disorder, gait and limb impairment treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2991529A1 CA2991529A1 (en) | 2017-01-12 |
| CA2991529C true CA2991529C (en) | 2021-01-05 |
Family
ID=57686013
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2991529A Active CA2991529C (en) | 2015-07-08 | 2016-06-14 | Pre-frontal cortex processing disorder, gait and limb impairment treatment |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP3319603B1 (enExample) |
| JP (2) | JP6930969B2 (enExample) |
| CN (1) | CN108025003B (enExample) |
| CA (1) | CA2991529C (enExample) |
| MX (1) | MX2017016910A (enExample) |
| WO (1) | WO2017007577A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2991529C (en) * | 2015-07-08 | 2021-01-05 | Gilrose Pharmaceuticals, Llc | Pre-frontal cortex processing disorder, gait and limb impairment treatment |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2157880A (en) | 1937-01-22 | 1939-05-09 | Electrical Res Prod Inc | Recording system |
| US2507631A (en) | 1944-01-19 | 1950-05-16 | Ciba Pharm Prod Inc | Pyridine and piperidine compounds and process of making same |
| US4145083A (en) | 1977-06-17 | 1979-03-20 | Urban Frank K | Therapeutic chair for cerebral palsy child |
| US4844075A (en) | 1984-01-09 | 1989-07-04 | Pain Suppression Labs, Inc. | Transcranial stimulation for the treatment of cerebral palsy |
| GB9120306D0 (en) | 1991-09-24 | 1991-11-06 | Graham Herbert K | Method and compositions for the treatment of cerebral palsy |
| US6355656B1 (en) | 1995-12-04 | 2002-03-12 | Celgene Corporation | Phenidate drug formulations having diminished abuse potential |
| US5908850A (en) | 1995-12-04 | 1999-06-01 | Celgene Corporation | Method of treating attention deficit disorders with d-threo methylphenidate |
| US6121261A (en) | 1997-11-19 | 2000-09-19 | Merck & Co., Inc. | Method for treating attention deficit disorder |
| RU2185106C1 (ru) | 2001-07-12 | 2002-07-20 | Свадовский Александр Игоревич | Способ нейрохирургического лечения детского церебрального паралича |
| US7973057B2 (en) * | 2003-09-17 | 2011-07-05 | The United States Of America As Represented By The Department Of Health And Human Services | Thalidomide analogs |
| US8952895B2 (en) * | 2011-06-03 | 2015-02-10 | Apple Inc. | Motion-based device operations |
| US20050215521A1 (en) | 2003-12-22 | 2005-09-29 | Karim Lalji | Modafinil combination therapy for improving sleep quality |
| US20050182097A1 (en) | 2003-12-30 | 2005-08-18 | Zeldis Jerome B. | Methods and compositions using thalidomide for the treatment and management of central nervous system disorders or diseases |
| AU2006204699B2 (en) * | 2005-01-13 | 2012-04-26 | Sirtris Pharmaceuticals, Inc. | Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders |
| EP2338881A1 (en) | 2005-02-23 | 2011-06-29 | Prexa Pharmaceuticals, Inc. | Dopamine transporter inhibitors for use in treatment of movement disorders and other CNS indications |
| CA2686155C (en) * | 2006-05-22 | 2016-11-15 | The Board Of Trustees Of The Leland Stanford Junior University | Pharmacological treatment of cognitive impairment |
| EP1985276A1 (en) | 2007-04-26 | 2008-10-29 | Merz Pharma GmbH & Co. KGaA | Treatment of movement disorders by a combined use of a chemodenervating agent and automated movement therapy |
| US20110270345A1 (en) | 2007-08-11 | 2011-11-03 | Johns Hopkins University | Focal noninvasive stimulation of the sensory cortex of a subject with cerebral palsy |
| MX2011001384A (es) * | 2008-08-06 | 2011-09-27 | Gosforth Ct Holdings Pty Ltd | Composiciones y metodos para tratar trastornos psiquiatricos. |
| WO2011011528A1 (en) * | 2009-07-23 | 2011-01-27 | Musc Foundation For Research Development | Isopropylphenidate for the treatment of attention-deficit/hyperactivity disorder and fatigue-related disorders and conditions |
| WO2011085256A2 (en) * | 2010-01-07 | 2011-07-14 | Vivus, Inc. | Treatment of obstructive sleep apnea syndrome with a combination of a carbonic anhydrase inhibitor and an additional active agent |
| CN102792513A (zh) * | 2010-03-01 | 2012-11-21 | 波士顿电力公司 | 具有平均温度及热点回授之热感测器装置 |
| EP2544688B1 (en) * | 2010-03-02 | 2016-09-07 | President and Fellows of Harvard College | Methods and compositions for treatment of angelman syndrome |
| US8287903B2 (en) | 2011-02-15 | 2012-10-16 | Tris Pharma Inc | Orally effective methylphenidate extended release powder and aqueous suspension product |
| US20140163070A1 (en) | 2012-05-17 | 2014-06-12 | Bruce Roseman | Treatment for cerebral palsy impaired speech in children |
| US9682073B2 (en) * | 2011-05-19 | 2017-06-20 | Gilrose Pharmaceuticals, Llc | Pre-frontal cortex processing disorder gait and limb impairments treatment |
| US8883815B2 (en) | 2011-05-19 | 2014-11-11 | Gilrose Pharmaceuticals, Llc | Treatment for cerebral palsy impaired speech in children |
| WO2012158892A2 (en) * | 2011-05-19 | 2012-11-22 | Bruce Roseman | A method of treating apraxia of speech in children |
| KR20130016127A (ko) * | 2011-08-04 | 2013-02-14 | 의료법인 성광의료재단 | 외상성 뇌손상의 치료 |
| KR102080154B1 (ko) * | 2011-12-08 | 2020-02-21 | 아포스-메디컬 앤드 스포츠 테크놀로지즈 엘티디. | 신경 장애들을 치료하기 위한 장치 |
| EP2705841A1 (en) * | 2012-09-05 | 2014-03-12 | Pharnext | Combinations of nootropic agents for treating cognitive dysfunctions |
| US9305307B2 (en) * | 2013-07-15 | 2016-04-05 | Google Inc. | Selecting content associated with a collection of entities |
| ES2719703T3 (es) * | 2013-11-08 | 2019-07-12 | Noramco Inc | Procedimiento para la preparación de metilfenidato y sus sales farmacéuticas |
| CA2991529C (en) * | 2015-07-08 | 2021-01-05 | Gilrose Pharmaceuticals, Llc | Pre-frontal cortex processing disorder, gait and limb impairment treatment |
-
2016
- 2016-06-14 CA CA2991529A patent/CA2991529C/en active Active
- 2016-06-14 WO PCT/US2016/037367 patent/WO2017007577A1/en not_active Ceased
- 2016-06-14 EP EP16821790.9A patent/EP3319603B1/en active Active
- 2016-06-14 MX MX2017016910A patent/MX2017016910A/es unknown
- 2016-06-14 CN CN201680052229.7A patent/CN108025003B/zh active Active
- 2016-06-14 JP JP2018520374A patent/JP6930969B2/ja active Active
-
2021
- 2021-02-08 JP JP2021018221A patent/JP7350794B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3319603A1 (en) | 2018-05-16 |
| JP7350794B2 (ja) | 2023-09-26 |
| EP3319603A4 (en) | 2019-03-13 |
| MX2017016910A (es) | 2018-08-15 |
| JP2018521127A (ja) | 2018-08-02 |
| CN108025003B (zh) | 2021-07-13 |
| JP6930969B2 (ja) | 2021-09-01 |
| EP3319603B1 (en) | 2021-11-17 |
| WO2017007577A1 (en) | 2017-01-12 |
| CA2991529A1 (en) | 2017-01-12 |
| CN108025003A (zh) | 2018-05-11 |
| JP2021088571A (ja) | 2021-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9408838B2 (en) | Treatment for cerebral palsy gait impairment | |
| KR102785448B1 (ko) | 신경퇴행성 질병을 위한 치료제 | |
| AU2017236177B2 (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
| WO2014019268A1 (zh) | 一种促进神经损伤修复的药物组合物及其应用 | |
| US9682073B2 (en) | Pre-frontal cortex processing disorder gait and limb impairments treatment | |
| US11102953B2 (en) | Pre-frontal cortex processing disorder speech, gait and limb impairments treatment | |
| KR102549684B1 (ko) | 신경퇴행성 질병에 대한 치료제 | |
| JP7350794B2 (ja) | 前頭前皮質プロセシング疾患、歩行及び四肢障害の治療 | |
| KR20170131543A (ko) | 근위축성 측삭 경화증을 치료하기 위한 비오틴 | |
| A. Sackner | Whole Body Periodic Acceleration:" Passive Exercise" for Parkinson’s disease | |
| RU2594252C1 (ru) | Способ реабилитации больных алкогольной полинейропатией | |
| JP2019517516A (ja) | Ｓｍａの新規な処置 | |
| Lockley et al. | Physical management of spasticity | |
| US20090124606A1 (en) | Composition for Treatment of Psychosis | |
| Stone et al. | VITAMIN B AND E THERAPY IN TABES DORSALIS:(Preliminary Report on the Use of Wheat Germ Oil, Vitamin B Complex and Intraspinal Administration of Thiamin Chloride) | |
| Mandelcorn et al. | A preliminary study of the efficacy of ondansetron in the treatment of ataxia, poor balance and incoordination from brain injury | |
| WO2004105756A2 (en) | Combination comprising (a) a neuroprotecting agent and (b) an agent binding to gadph and pharmaceutical use thereof | |
| CA2735949C (en) | Use of ribose in lessening the clinical symptoms of aberrant firing of neurons | |
| HK1262519A1 (en) | New treatment of sma | |
| WO2017111052A1 (ja) | 自己免疫疾患治療剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20180308 |